CN1099997A - Generation of nitric oxide from air for medical uses - Google Patents

Abstract

A system for producing a mixture of nitrogen oxide and air for medical use. The present invention can produce NO at any place without limitation using only air and power. The arc chamber 4 is provided by electrodes 5 separated by an air gap 9 . A circuit 7 supplies a high voltage to the electrode 5 and an arc discharge is generated on the electrode 5 . The arc discharge produces nitrogen oxides mixed with air. The nitric oxide and air mixture is further purified and mixed with other gases and/or pulmonary therapeutic agents and this therapeutically effective gas mixture is delivered to different organs of the body using organ specific attachments.

Description

The present invention relates to a method and system for producing nitric oxide mixed with air or other gases for medical use.

Nitric oxide (NO) is essential to many biological systems (G. Kolada, The New York Times, 2 July 1991). Kolada points to nitric oxide as a mediator in blood pressure control, helps the immune system kill parasites that invade cells, stops cancer cells from dividing, transmits signals between brain cells, and can be helpful in debilitating stroke or Huntington patients The large number of dead brain cells has an effect.

Nitric oxide has been shown to mediate relaxation of gastric smooth muscle (K.M. Desai et al., Nature, Vol. 351, June 6, 1991, p. 477). demonstrated that a non-adrenergic, non-cholinergic (NANC) neurotransmitter was well suited to mediate relaxation in the isolated stomach of guinea pigs, and they also showed that this NANC neurotransmitter was incompatible with L-arginine The derived nitric oxides were indistinguishable. The authors concluded that it is likely that nitric oxide is a definitive and common mediator of smooth muscle relaxation.

Smooth muscle is found, for example, on the walls of blood vessels, bronchial tubes, the gastrointestinal system, and the urogenital system. Administration of nitric oxide by inhalation into the lungs results in local smooth muscle relaxation without systemic side effects. This feature can be used to treat bronchoconstriction and pulmonary hypertension, pneumonia, and more.

Nitric oxide is now known to be an important naturally occurring local cytokine, the so-called intradermally acquired relaxation factor. This factor is produced by nitric oxide synthase (now known as a family of at least six enzymes) from arginine. Many cells (i.e., endothelial cells, which line blood vessels, bronchi, large intestine, bladder, uterus, and other on hollow organs). Once nitric oxide is released, it will rapidly combine with guanylate cyclase in smooth muscle cells, increase cyclic guanylate monophosphate (cyclic GMP), and reduce intracellular calcium concentration, thereby causing smooth muscle relaxation.

Inhaled nitric oxide, as demonstrated in several animal and human representative pilot studies, is an effective local pulmonary vasodilator and bronchodilator without systemic effects. Nitric oxide can greatly improve the ventilation matching of the perfusate, thereby improving the oxygen delivery efficiency of the damaged lung lobe and increasing the oxygen concentration of the artery. To date, NO is the only pulmonary vasoactive agent with such selectivity and thus has great potential for the treatment of acute and chronic lung diseases of bronchoconstriction and vasoconstriction.

Bronchodilators are medications used to relieve aviation reactions or conversely for bronchospasm due to various diseases such as asthma, exacerbated chronic pulmonary obstructive disease, allergies and anaphylaxis and others. Several bronchodilators have been used, each with its own tolerability and unwanted side effects depending on its mode of action.

β-antagonists, represented by epinephrine and isoproterenol, cause bronchodilation by stimulating receptors to increase the concentration of adenine cyclase and the production of intracellular cyclic adenosine monophosphate (AMP). They can be administered by aerosol, orally or parenterally. Administration of these agents can cause significant cardiac adverse effects such as tachycardia, palpitations, changes in blood pressure and other side effects including anxiety, tremors, nausea and headache. Newer β2-selective antagonists, such as albuterol, have fewer side effects and are slower in action.

Theophylline preparations are less bronchodilatory than beta antagonists and have a narrower therapeutic toxic window. The mechanism of action of bronchodilators corresponding to theophylline may be via cyclic AMP. Common side effects caused by theophylline are nervousness, nausea, and vomiting. Anorexia and headaches. Additionally, theophylline can cause irregular heartbeats and heart attacks if taken in large doses.

Anticholinergics, such as atropine methyl nitrate and ipratropium bromide, are effective bronchodilators when administered by aerosol with fewer side effects. However, its action is slow, and it may take 60 to 90 minutes to reach peak bronchodilation.

Nitric Oxide is unique in that it combines the benefits of rapid action in seconds with no systemic effects. Once inhaled, it spreads through the pulmonary vessels into the bloodstream where it binds to hemoglobin and is rapidly inactivated. Thus, the bronchodilation of inhaled nitric oxide is restricted to the air intake passages and the vasodilator of inhaled nitric oxide is restricted to the pulmonary vessels.

The specific property of nitric oxide to selectively dilate pulmonary arterial blood vessels can also be used in the treatment of acute or chronic pulmonary arterial blood pressure, defined as mean pulmonary arterial blood pressure 12 to 15 mmHg above normal.

Acute pulmonary arterial blood pressure is produced as a result of constriction of the pulmonary vessels in response to sudden hypoxia due to, for example, pneumonia, pulmonary embolism, or acidosis. Acute pulmonary arterial blood pressure is a potentially reversible phenomenon. Factors that normalize pulmonary blood pressure. But persistent hypoxia leads to permanent structural changes in the pulmonary vessels, and chronic pulmonary arterial blood pressure ensues. The main causes of chronic pulmonary hypertension are obstructive pulmonary disease, recurrent multiple small emboli, heart disease such as mitral stenosis, or atrial septal defect, and idiopathic primary pulmonary hypertension. Pulmonary blood pressure is also associated with several other fatal conditions, such as senile respiratory distress syndrome and persistent pulmonary blood pressure in newborns.

To date, several vasodilator drugs have been attempted to treat pulmonary arterial blood pressure, including nitroprusside, hydralazine, nifedipine, captopril, and others, among others. The major limitation of these agents is that they lower both pulmonary and systemic blood pressure indiscriminately. In contrast, the vasodilation effect of inhaled nitric oxide is confined to the pulmonary arterial vessels, thus bringing a revolutionary advantage to therapy.

An inhaler for the delivery of nitric oxide is described in US Patent Application Serial No. 07/767,234, filed September 23, 1991, assigned to the present applicant, which is incorporated herein by reference.

The present invention provides a system for producing a mixture of nitric oxide and air or other gases for medical use. The system produces nitrogen oxides during an arc discharge using only air and a power source. The present invention can produce nitrogen oxide in any occasion without limitation.

A patient can take a portable inhaler of the system of the present invention wherever he or she is going and use the inhaler to treat asthma attacks or other symptoms of bronchoconstriction, acute respiratory failure, or reversible pulmonary vasoconstriction. In addition, the patient may vary the amount of nitric oxide inhaled due to changes in his or her medical condition.

The system of the present invention can be used in medical or emergency treatment for the production of NO and the delivery of NO mixed with other gases to achieve therapeutically effective concentrations to specific organs of the human body. Nitric oxide relaxes smooth muscle almost immediately after delivery; and the action of nitric oxide is confined to the organ being treated.

It is an object of the present invention to provide an inhaler which produces an air or other gaseous NO mixture for respiratory therapy; which uses a power source to create an electric arc between a pair of electrodes separated by an air gap. Air is continuously introduced into an arc chamber containing electrodes through an air inlet. The inhaler has an electrical circuit for supplying a high voltage to the electrodes, wherein the high voltage peaks are sufficient to create an arc between the air gaps of the electrodes. Arc discharge produces nitrogen oxides. The generated nitric oxide mixed with air is sent out through an outlet and inhaled by the patient.

A preferred embodiment of this object of the invention may consist of electrodes placed in the arc chamber made of two axially aligned metal rods, the tips of which are separated by an adjustable air gap, the circuit of the inhaler comprising a high voltage transformer , the primary coil is connected to a power supply, and a parallel RCL circuit is connected in parallel with the secondary and high-voltage coil of the transformer. The resistive element of the parallel RCL circuit consists of high voltage electrodes separated by an air gap. The air inlet of the inhaler has a filter, which is used to filter the air sucked through the air inlet to prevent small liquid droplets or solid particles from entering the arc chamber. The size of the inhaler is required to be portable and weigh less than about 1 kg.

A preferred embodiment of this object of the invention may also include a cleaning device for removing low levels of nitrogen dioxide and ozone formed in the arc chamber. The purge device shall be arranged so that the gases leaving the arc chamber are forced to pass through the purge device before being released from the inhaler. The outlet has a mouthpiece for direct suction of the gas mixture forced to pass through the purification device from the arc chamber.

A preferred embodiment of this object of the present invention may also include an air inlet member with a series of selected restricted orifices for allowing an adjustable flow of air to enter the suction port and to allow the air to flow through the mouthpiece when inhaled into the body. Air is mixed with the gas mixture coming out of the arc chamber. The purification device contains _O3 and _NO2 purification agent, for example, soda lime or calcium barium absorbent.

A preferred embodiment of this object of the invention may also include a gas pump for forcing the gas mixture through the purification means to output from the outlet. The gas mixture can then be passed into an oxygen mask or forced into a room or chamber, such as an incubator.

Another object of the present invention is to provide a system for the continuous production of a mixture of air and nitric oxide for use in the treatment of medical conditions requiring direct delivery of such a mixture to an organ of the body. The system has an arc chamber with a pair of electrodes separated by an air gap, and nitrogen oxides are produced by an arc discharge between the electrodes. The system also includes a circuit for supplying high voltage to the electrodes. The high voltage spikes are sufficient to arc across the air gap. The system has an air inlet for continuous introduction of air into the arc chamber. A gas delivery system used to purify and deliver the produced nitric oxide mixed with air or another gas to the organs of the body, for example using a mechanical ventilator or ventilator to remove the mixture (other gases, such as anesthetic gases can also added) into the lungs.

Preferred embodiments of this object of the present invention may also include a gas inlet manifold for introducing selected gases into the delivery system for precise mixing of the selected gases with the generated nitrogen oxide gas mixture and for delivery The system delivers the mixed gas mixture.

A preferred embodiment of this object of the invention may also include a gas analyzer (eg NOx chemiluminescence analyzer) for analyzing the concentration of the individual components of said gas mixture delivered by the delivery system. A regulator system is connected to the analyzer and the gas inlet manifold for regulating the concentrations of the individual component gases (eg, breathing oxygen) introduced into the delivery system in predetermined prescribed doses.

Other features and advantages of the invention appear from the following description of preferred embodiments and from the claims.

Figure 1 is a schematic cross-sectional view of one embodiment of a portable inhaler of the present invention.

Fig. 2 shows a schematic diagram of a high voltage generating circuit used in the embodiment.

Figure 3 is a schematic cross-sectional view of an embodiment of a large inhaler for a room.

Figure 4 is a schematic cross-sectional view of an embodiment of an inhaler system for use in therapeutic and emergency care settings.

Figure 5 is a schematic cross-sectional view of another embodiment for delivering NO to various organs of the body, including mechanical ventilators for assisting breathing.

Figure 6 is a graph illustrating the NO gas flow concentration as a function of the average current in the primary coil of a high voltage transformer and the air flow through the arc chamber. The gap between the electrodes is 3 mm, V in the figure is the air flow rate, L/min, and the NO concentration is the volume per million (PPM).

Figure 7 is a graph illustrating the NO gas flow concentration as a function of the current in the primary winding of a high voltage transformer and the air flow through the arc chamber. The electrode gap is 5 mm, V in the figure is the air flow rate, liters per minute, and the NO concentration is the million volume content (PPM).

Fig. 8 is a diagram showing changes in pulmonary arterial pressure during different experimental stages of NO inhalation in an awake sheep with acute pulmonary arterial blood pressure symptoms due to injection of U46619. NO is produced by electrical discharge and exhibits remarkable pulmonary vasodilatory properties.

FIG. 1 shows a portable inhaler with an air inlet 2 for air into the arc chamber 4 . Inlet 2 includes a one-way valve and a 0.22 micron filter 3 manufactured by Millipore Corporation. This filter removes bacteria and unwanted components present in the inhaled air. The arc chamber 4 is made of electrically insulating material and has two axially placed electrodes 5 separated by an air gap 9 . A high voltage generating circuit 7 is connected to the electrode 5 . The arc chamber 4 is connected to a soda lime filter 13 which is attached to the suction chamber 14 . The suction chamber 14 has a mouthpiece 17 and an air introduction member 15 consisting of a series of optionally restricted orifices. Each aperture has a filter 16 for filtering liquid droplets and solid particles present in the air. The gas passage system (comprising the inlet 12, the filters 3, 13, 16 and the inhalation chamber 14) is designed to be easily inhaled by the patient with relatively little resistance. Different kinds of filters 3, 16 can be used depending on the environmental conditions in which the inhaler is used. The inhaler is closed with a housing 19 made of Teflon, or with another high voltage insulating material. A power switch 11 with an indicator light 12 controls the operation of the inhaler.

Referring to Fig. 2, a high voltage generating circuit 7 includes a step-up transformer 24 with primary and secondary coils. The primary coil is connected to the power supply 21, and the secondary coil—high voltage coil 25 is connected to a parallel RCL circuit. The voltage introduced by the power supply 21 is regulated by the autotransformer 23 and raised to a high voltage in the secondary coil 25 . Other circuits that generate high-energy voltages, such as Tesla coils, can also be used. Electrical energy is temporarily stored in a capacitor 26 , charged to the breakdown voltage, and subsequently discharged through the air gap 9 . The air gap 9 defined by the two electrodes 5 determines the resistance of the two electrode arrangement. The breakdown voltage (about 20kv) is proportional to the width of the air gap and the shape of the electrode 5 .

Arc discharge produces a plasma that is confined between air gaps. In the plasma, oxygen and nitrogen molecules break apart and atoms ionize to produce ozone and NO. A small portion of the nitrogen oxides is then oxidized to higher oxides, forming nitrogen dioxide. However, this process is only significant in the temperature rising stage. The concentrations of NO, NO2 and O3 depend on the width of the air gap and the duration of the arc, and are expressed in parts per million by volume (ppm).

During operation of the inhaler, gas is drawn from the arc chamber 4 through the soda lime filter 13 and the inhalation chamber 16 and the gas mixture is inhaled by the patient through the mouthpiece 17 . The soda lime filter 13 removes toxic NO2 and O3 from the gas mixture, preventing them from entering the intake, so the mixture contains only the original air and NO. At the same time, additional air enters the inhaler through the inlet 2 and is sucked into the arc chamber 4, and the subsequent arc discharge ionizes N2 and O2 molecules to form NO, NO2 and O3, and the process repeats. The concentration of NO produced in the arc discharge chamber is between 10 and 250 ppm, depending on the resistance of the air gap 9 and the energy delivered to the electrode 5 . Medically effective NO concentrations range (for a portable inhaler) from about 1 ppm to 180 ppm. To achieve these values for the NO concentration in the inhaler, an additional air mixing inlet 15 with a set of openings of different sizes is used. Breathing gas by the patient through the mouthpiece 17 of the inhaler automatically mixes the gas in the arc chamber with the air entering the inlet 15 . To vary the concentration of NO, the patient can select different sized openings to increase or decrease the amount of air passing through the inlet 15 into the inhalation chamber 16 . In another embodiment, where the patient is unable to inhale the gas on his own, an air pump 18 or other pressure source (eg, ventilator) is disposed within the inhalation chamber 16 to force the gas mixture out of the inhaler. At this point the port pump can be connected to an endotracheal tube or an endotracheal selective port tube. This electric NO generator can be connected to a standard pneumatic multi-dose inhaler (MDi), which sprays a chemically synthesized bronchodilator (eg, terbutaline, corticosteroid, etc.) within 15. In the next few seconds, the inhaled electrically produced NO produces immediate bronchodilation and the MDi for long-term bronchodilation. This will increase the efficacy of MDi, because NO dilates the bronchi, improving drug delivery. Other inhaled drugs, such as surfactants, mucopolysaccharases, etc., can also be infused together with (either before or in conjunction with) NO produced from electricity.

In a preferred embodiment, the inhaler is a portable, lightweight, hand-held battery-operated device measuring less than about 20 x 20 x 10 cm. A patient suffering from asthma or pulmonary hypertension can carry the inhaler and use it according to his or her needs. At the beginning, the patient may need to inhale a large dose of nitric oxide, for example at a concentration of 150 ppm nitric oxide (in air), which can be done by closing the air inlet 15 . When the patient's bronchi and/or pulmonary vessels are dilated, he or she can reduce the concentration by selecting a larger opening. Hand-held inhalers provide an unrestricted source of NO.

In another preferred embodiment, the inhaler is a large system for room use. Referring to FIG. 3 , an air pump 32 forces air into an arc chamber 35 . A filter 31 at the inlet 30 removes unwanted components present in the inhaled air. As in the portable inhaler embodiment, the arc chamber is made of electrically insulating material and has two electrodes 36 separated by an air gap. The electrodes 36 are connected to a high voltage circuit 34 powered by a standard 110v, 60Hz (or 220v, 50Hz) power outlet. The nitrogen oxides, nitrogen dioxide and ozone formed in the arc discharge are forced through a soda lime filter 38 . The filter 38 absorbs NO2 and O3 from the gas mixture and the nitric oxide mixed with air or other gas (eg O2) is pumped out the outlet 39 which can be connected to a mask. For another preferred embodiment, the resulting gas mixture is pumped through outlet 39 into an incubator or into a room.

In another preferred embodiment, the inhaler is a device used in medical or emergency care facilities. The size of the inhaler depends on its specific use. The larger unit is powered from a standard 110v 60Hz power outlet, and the portable inhaler uses a 9v battery. Referring to Figure 4, an air cylinder and regulator 40 were used to supply air at a pressure of 17 psi to the NO generating system. Similar to the alternative embodiment, the system has an inlet 42, an arc chamber 44 with electrodes 46, and a soda lime filter 48. The mixed gas of NO and air is generated in the same manner as described above. In addition, this system has a 5 liter mixing bag 50 connected to the outlet 58 . The air mixing bag 50 is used to mix the air coming in from the inlet 59 with the oxygen or oxygen-enriched N2 mixed gas coming in from the inlet 52 . The mixture of air, oxygen and NO is introduced through outlet 58 to a respirator or an oxygen mask. An inspired oxygen fraction (Fio2) meter 56 is connected to outlet 58 to measure the volume fraction of oxygen.

In another preferred embodiment, the present invention provides a system for use in a medical facility, such as in an intensive care facility or in an emergency room. Referring to Figure 5, the system utilizes an air source 60 at a pressure of about 50 psi. Arc chambers of such large systems may include more than one pair of electrodes in order to increase nitrogen oxide production. The setup of this device is similar to that in FIGS. 1 , 3 and 4 . Pressurized air is introduced via a regulator 62 into an arc chamber 64 where electrodes 66 are located. A soda lime filter 68 absorbs unwanted by-products (ie NO2 and O3) of the arc discharge process. The mixture of air and NO was mixed with oxygen from inlet 72 using a Bird mixer 70 . A FiO2 meter 74 is connected to outlet 76 to measure the oxygen ratio. The system is powered by a standard power supply (110v, 60Hz). In addition, the device has an automatic regulator system connected to the air inlet and a gas analyzer connected to the gas pump. The gas analyzer monitors the amount of nitrogen oxides and other gases in the gas mixture delivered to the body organs; in addition, the analyzer controls the automatic regulator system to maintain the scientific concentration of NO according to a predetermined schedule. This embodiment can be connected to a mechanical ventilator for providing the NO gas mixture for ventilation therapy.

Various accessories (not shown in Fig. 5) can be installed on the outlet 76 to deliver the mixture of various gases and NO to the designated organs. For example, outlet 76 could be fitted with a means to deliver NO to the tip of the Foley catheter to facilitate catheter insertion into the urinary system or bladder.

example 1

Test curves for devices with electrode gaps of 3 and 5 mm are shown in Figures 6 and 7, respectively. Different flow rates (V) of air (ranging from 1 L/min to 10 L/min) are introduced into the arc chamber. The current of the primary coil of the high-voltage transformer is changed from 250μA to 1.25mA to increase the power of the high-voltage circuit. The output from the arc chamber was introduced into a NOx chemiluminescence gas analyzer to determine the content of different nitrogen oxides.

Referring to Figure 6, the concentration of NO, expressed in parts per million, increases unidirectionally with the energy supplied to the electrode (which has an air gap of 3 mm). The highest NO concentration is obtained at an airflow (V) of 1 L/min; further increases in air flow will decrease the NO concentration.

For an air gap of 5 mm, almost the same trend can be observed, shown in Fig. 7. However, due to the larger air gap, the plasma generated by the arc discharge is also larger, so the concentration of NO generated by the arc discharge is also higher. The voltage necessary to break down the dielectric and create an electric spark between the two electrodes is about 20 kV. The larger the electrode separation, the higher the breakdown voltage is required.

The amount of ozone generated in the arc discharge was measured with a UV photometric ozone analyzer. A NO generating system with a spark gap of 3 mm generates 0.01 ppm of ozone in the arc discharge chamber at an air flow rate of 2 liters/min. This O3 concentration is indeed lower than the ozone exposure limit established by the Occupational Safety and Health Administration of the US Department of Labor. Likewise, measured concentrations of NO2 were low (<2% NO concentration).

The selected operation is about 1.1 mA when using an air flow of about 1.5 1/m. However, these parameters depend on the shape of the electrodes, air humidity and other factors.

Example 2

A 30 kg male Dorset sheep, after a tracheostomy, was inserted with a 7 slenderness ratio pulmonary artery Swan-Ganz cannula and a femoral artery cannula for continuous monitoring of pulmonary and systemic arterial blood pressure. Awake sheep were continuously infused with 0.6 μg/kg/min of U46619 (Upjohn Pharmaceuticals), a stable thromboxane that mimicked acute pulmonary vasoconstriction and hypertensive symptoms. Infusion of U46619 increased pulmonary arterial blood pressure (PAP) by 79%, from a mean of 19mmHg to 33mmHg. The arc chamber and circuitry used to generate the mixture of air and NO was the same as that shown in FIG. 4 . Once the air with 10ppm NO content was inhaled, PAP immediately decreased by 25%, down to 25mmHg, confirming the vasodilation effect of NO (produced by 5mm air gap high-voltage direct current spark). Figure 8 shows the curves of inhalation of different concentrations of NO (measured by chemiluminescence) versus mean PAP. When increasing the current to get 15ppm inhaled NO concentration, PAP dropped to the level of 23mmHg. Continuing to increase the amount of inhaled NO up to 40ppm can further reduce PAP, reaching the level of 18mmHg without injecting U46619. Then, only air was delivered to the lungs of the sheep, and the PAP was rapidly increased to 34mmHg due to the unopposed effect of the U46619 infusion. Systemic arterial blood pressure (SAP) remained unchanged at 94 mmHg throughout the NO inhalation trial. The fact that SAP remains unchanged proves that inhaled NO has a dilative effect only locally in the pulmonary circulation vessels.

Other embodiments of the invention are within the scope of the claims. The "air" referred to in the claims includes not only normal air but also other mixed gases containing N2 and O2. Various other gases, such as anesthetics, supplemental oxygen, other classes of bronchodilators (eg, multidose inhalers), or other pulmonary agents (eg, surfactants, mucopolysaccharidases, various anti-inflammatory drugs) , etc., can also be added to the mixed gas of NO and air produced by the embodiment of the present invention.

Claims (25)

1, a kind of inhaler that is used for the generation mixture of respiratory system treatment, wherein this mixture comprises air and nitrogen oxide, and described inhaler uses an air and a power supply, and described inhaler comprises:

Arc chamber with a pair of electrode that is separated by air-gap is used for producing nitrogen oxide by arc discharge between described electrode,

One is used for providing highly compressed circuit to described electrode, and described high pressure has a peak value to be enough to produce electric arc between described air-gap,

Gas feed part that is used for providing continuously the described arc chamber of air admission and

The exit portion that the mixture that is used to discharge described generation smokes to patient.

2, the inhaler of claim 1, the described electrode of wherein said arc chamber are two axially metal bars of collimation, and their tip is separated by described air-gap.

3, the inhaler of claim 2, wherein said circuit comprises:

One has the elementary high-tension transformer that is connected in power supply,

A RCL circuit in parallel is parallel to secondary, the high-pressure side of described high-tension transformer, and the resistive element of wherein said RCL circuit in parallel comprises the high-field electrode that is separated by described air-gap.

4, claim 1,2 or 3 inhaler, wherein said air intlet partly comprises a filter, is used to filter the air by described import department, enters described arc chamber to stop drop or solid particle.

5, the inhaler of claim 4, the size of wherein said inhaler are less than about 20 * 20 * 10cm, and its weight is less than about 1kg.

6, the inhaler of claim 4, comprising

One purifier is used to remove the nitrogen dioxide and the ozone that generate in described arc chamber, the setting of described purifier be for make gas leave described arc chamber be forced through before from described inhaler, discharging described purifier and

One mouthpiece in described exit is used for directly sucking described admixture of gas from described arc chamber through described purifier.

7, the inhaler of claim 6, wherein further comprise air intlet parts, it has the limiting orifice of a series of selections, the air that is used for controlling flow is incorporated into described suction inlet place, and uses the described admixture of gas that obtains from described arc chamber to mix with described air when sucking described mixture by described mouthpiece.

8, the inhaler of claim 6, wherein said purifier contains the cleanser for O3 and NO2.

9, claim 1 or 2 inhaler further comprise

One purifier is used to remove the nitrogen dioxide and the ozone that generate in described arc chamber, the setting of described purifier be for make admixture of gas leave described arc chamber be forced through described purifier and

One air pump is used to force described admixture of gas to discharge from described exit.

10, be used for the system that continuously preparation comprises the mixture of air and nitrogen oxide, described mixture directly need be delivered to patient's organ for medical therapy, described system comprises

Arc chamber with a pair of electrode that is separated by air-gap is used for producing nitrogen oxide by arc discharge between described electrode,

One is used for providing highly compressed circuit to described electrode, and described high pressure has a peak value to be enough to produce electric arc between described air-gap,

One be used for providing continuously gas feed part that air or row's ventilation enter described arc chamber and

Mixture that is used to discharge described generation induction system to the organ of human body.

11, the system of claim 10, wherein said induction system are specially on the specific organ of the described mixture to of direct discharge.

12, the system of claim 11, further comprise a gas feed manifold, be used for selected gas is incorporated into described induction system, described mixture is mixed with the gas of described selection and discharge described mixture by described induction system.

13, claim 12 further comprises

One gas analyser, be used to analyze described each composition of admixture of gas of discharging by described induction system concentration and

One regulating system is connected on described analyser and the described gas feed manifold, is used for introducing according to predetermined prescription measure control the concentration of described each composition of induction system.

14, a kind of preparation is used for the method for the mixture of respiratory system treatment, and wherein this mixture comprises air and nitrogen oxide, and described method is used an air and a power supply, and wherein step comprises:

By the arc chamber of air intlet introducing air admission one inhaler,

Provide high voltage to by air-gap separately and place on the electrode assembly of described arc chamber, described high pressure has a peak value to be enough to produce electric arc between described air-gap,

By between described electrode by the arc discharge of described high-voltage charging produce nitrogen oxide and

Discharge the mixture of described generation by an outlet.

15, the method for claim 14 wherein further comprises in order to prevent that drop or solid particle from entering described arc chamber, filters the step of the air of introducing through described import department.

16, the method for claim 14 wherein further comprises the nitrogen dioxide and the ozone that produce in order to remove in described arc discharge process, purify the step of the gas of sucking-off from described arc chamber.

17, the method for claim 14 comprises further wherein from the nitrogen oxide of described arc chamber inspiration and the described mixture of air and carries out blended step with the air of introducing through air intlet parts that these parts have the limiting holes of a series of selections.

18, the method for claim 14 wherein further comprises the nitrogen dioxide and the ozone that produce in order to remove in described arc discharge process, purify the step of the gas of inspiration from described arc chamber.

19, the method for claim 14 wherein further comprises and uses an air pump to force described admixture of gas to be discharged from described outlet.

20, a kind of preparation is used for the method for the nitrogen oxide of medical therapy, and by directly the described admixture of gas of organ particular delivery being carried out, wherein step comprises:

Introduce air and enter into the arc chamber of described system through an air intlet,

Provide high voltage to by air-gap separately and place on the electrode assembly of described arc chamber, described high pressure has a peak value to be enough to produce electric arc between described air-gap,

By between described electrode by the arc discharge of described high-voltage charging produce nitrogen oxide and

To use with the nitrogen oxide of the blended described generation of air of passing through an induction system and discharge, this induction system design is the certain organs that is used for described admixture of gas is transported to patient's health.

21, the method for claim 20, wherein said nitrogen oxide is transported on the certain organs.

22, the method for claim 20, comprise further that wherein the selected gas of guiding enters into described induction system through a gas feed manifold, the mixture that produces with described nitrogen oxide and air mixes with the gas of described selection, and the step of discharging described mixture by described induction system.

23, the method for claim 22, wherein further step comprises:

Analyze the described admixture of gas by described induction system discharge each composition concentration and

According to the concentration that each composition that enters into described induction system is regulated in predetermined prescription metering, a use therein regulating system is connected on gas analyser and the described gas feed manifold.

24, claim 1 or 10 device wherein further comprise the device that described mixture is added assist gas.

25, the method for claim 14 wherein further comprises the step of described mixture being added assist gas.

Images